BMI changes in pediatric type 1 narcolepsy under sodium oxybate treatment

Area of Science:

• Pediatric Neurology
• Endocrinology
• Pharmacology

Background:

• Pediatric narcolepsy type 1 (NT1) is frequently linked to overweight and obesity.
• Sodium oxybate (SO) is approved for narcolepsy with cataplexy in children aged 7+ and has shown potential for weight loss, but pediatric data are limited.

Purpose of the Study:

• To analyze the impact of pharmacological treatments, particularly sodium oxybate (SO), on body mass index (BMI) z-scores in pediatric patients with narcolepsy type 1 (NT1).
• To evaluate the longitudinal effects of SO treatment on weight management over a 4-year period.

Main Methods:

• Retrospective cohort study of 129 pediatric NT1 patients with a 4-year follow-up.
• Patients were categorized into three groups: SO monotherapy, SO-combined therapy, and no SO treatment.
• Body Mass Index (BMI) z-scores were analyzed at baseline and annually throughout the follow-up period.

Main Results:

• At baseline, 26.4% of patients were obese and 29.5% were overweight.
• Both SO monotherapy and SO-combined therapy groups showed significant BMI z-score reductions in the first year (p < 0.001 and p = 0.002, respectively).
• The SO-combined therapy group exhibited a further significant BMI z-score decrease in the second year (p = 0.037).
• Patients not treated with SO experienced a significant weight increase between years two and three.
• No significant BMI z-score changes were observed in SO-treated patients beyond the second year.

Conclusions:

• Sodium oxybate (SO) treatment is associated with favorable weight reduction in pediatric patients with narcolepsy type 1 (NT1) during the first year of therapy.
• The weight management effects of SO appear most pronounced in the initial year of treatment, with sustained benefits observed in combined therapy groups.